Stay updated on TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Sign up to get notified when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.

Latest updates to the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page
- ChecktodayChange DetectedDifference0.2%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new version of the study protocol for a Phase 2 trial involving talimogene laherparepvec, nivolumab, and trabectedin for advanced sarcoma, with a focus on progression-free survival at month 12. The primary objective and details about the study population have been clarified, while some previous details have been removed.SummaryDifference49%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to February 24, 2025.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe webpage has updated its date-related information, with new dates added for 2025 and 2030, while several previous dates have been removed. Additionally, a note regarding the last update has been modified.SummaryDifference2%
Stay in the know with updates to TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin
Enter your email address, and we'll notify you when there's something new on the TNT Clinical Trial: Talimogene + Nivolumab + Trabectedin page.